The need to select appropriate and effective drug therapy for patients with coronary artery disease (CAD) is one of the urgent tasks of modern cardiology. Despite the wide range of drugs available, selecting antianginal therapy is challenging for many patients with chronic types of CAD. Trimetazidine provides the desired clinical antianginal effect with high safety and good tolerability. The article presents three clinical cases of patients with chronic types of CAD, demonstrating effective use of trimetazidine in combined antianginal therapy.
No takes yet. Share an insight, caveat, or question.
D. I. Darenskiy (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: